

MENJONG SORIG PHARMACEUTICALS CORPORATION LTD.
THIMPHU, BHUTAN

STATEMENT OF COMPREHENSIVE INCOME
for the 2nd Quarter ended 30th June, 2022

PARTICULARS	Note No.	QUARTER ENDED	QUARTER ENDED
		30-06-2022	30-06-2021
		(Nu.)	(Nu.)
<u>REVENUE</u>			
Sales	15	18,782,195.22	22,849,390.99
Other Income	16	469,025.15	365,649.00
Total Revenue		19,251,220.37	23,215,039.99
<u>EXPENDITURE</u>			
Changes in Finished Goods & Work-in-Progress	17	3,509,106.85	1,076,467.49
Raw Materials & Packaging Materials Consumed	18	5,543,336.08	10,661,360.34
Manufacturing Expenses	19	897,841.00	983,794.36
Employee Benefit Expenses	20	5,950,247.00	5,999,491.00
Finance Cost	21	9,407.11	3,647.38
Depreciation & Amortization	01 & 02	2,226,808.32	2,259,750.62
Other Expenses	22	4,822,440.22	860,197.19
(Gain)/Loss on Foreign currency fluctuation		(3,228.56)	-
Total Expenditure		22,955,958.02	21,844,708.38
Profit/(Loss) before Tax		(3,704,737.65)	1,370,331.61
<u>Tax Expense</u>			
Current Tax		-	-
Net Profit/(Loss) for the Year		(3,704,737.65)	1,370,331.61
Other comprehensive income			
<i>Items that will not be reclassified to profit or loss</i>			
Measurements of post-employment benefit obligations		-	-
Income tax relating to above item		-	-
Other comprehensive income, net of tax		-	-
Total comprehensive income		(3,704,737.65)	1,370,331.61
Earnings per equity share			
Basic and diluted			
Notes on Financial Statements forms integral part of Accounts	23	(2.03)	0.75

This is the Statement of Comprehensive Income referred to in our report of even date.

Chairman

Chief Executive Officer

Director

Place : THIMPHU

Date : , 2022